Search

Heron Therapeutics Inc

Nyitva

SzektorEgészségügy

0.51

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

0.5

Maximum

0.54

Fő mutatók

By Trading Economics

Bevétel

-5.2M

-8.1M

Értékesítés

-5.9M

35M

Egy részvényre jutó nyereség

-0.04

Profit margin

-23.367

Munkavállalók

128

EBITDA

-6.8M

-7.6M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+292.16% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. aug. 10.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-143M

87M

Előző nyitás

0.51

Előző zárás

0.51

Hangulat hírek alapján

By Acuity

50%

50%

151 / 340 Rangsor szerint Healthcare

Heron Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 3. 23:56 UTC

News

Diversified Healthcare Trust reported second-quarter FFO of $0.16, exceeding estimates. Revenue fell short at $365.39 million, contributing to a decline in after-market trading.

2026. aug. 3. 23:56 UTC

News

First Solar Inc reported second-quarter revenue of $1.06 billion and a net profit of $423 million. Shares are higher in after-hours trading.

2026. aug. 3. 23:52 UTC

Social Media
Correlated Moves
News

Microsoft shares are lower in after-market hours amid a class action lawsuit alleging misrepresentation of its Copilot products' performance and competitive position.

2026. aug. 3. 23:51 UTC

News

Marvell Technology plans a conference call for August 27, 2026, and an Investor Day on October 6, 2026. Shares are higher in after-market trading.

2026. aug. 3. 23:51 UTC

News

Rivian Automotive raises 2026 capital expenditure guidance to $1.7B-$1.8B, shares trade higher in after-market hours amid focus on cost management and production scaling.

2026. aug. 3. 23:51 UTC

News

JELD-WEN Holding Inc. reported second-quarter revenue of $817.8 million, exceeding forecasts. The company raised its full-year revenue guidance, boosting after-market trading sentiment.

2026. aug. 3. 23:51 UTC

Social Media
News

Palantir Technologies reported Q2 revenue of $1.94 billion, exceeding expectations. Shares rose sharply in after-market hours following strong earnings and raised guidance.

2026. aug. 3. 23:51 UTC

Social Media
News

Snap Inc. reported a narrower net loss of $163.96 million and revenue of $1.60 billion, exceeding expectations. Shares rose during after-market trading.

2026. aug. 3. 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

2026. aug. 3. 23:46 UTC

News

CVS Health shares rose in after-market hours following a survey showing increased provider-payer trust scores and improved perceptions of digital tools in healthcare.

2026. aug. 3. 23:46 UTC

News

Alexandria Real Estate Equities reported a narrower net loss and FFO of $1.73, exceeding estimates. Shares traded higher in after-market hours.

2026. aug. 3. 23:46 UTC

Correlated Moves
News

Nova Ltd's after-market shares are higher, bolstered by strong analyst sentiment and a consensus price target of $603.38, reflecting a potential 54.4% return.

2026. aug. 3. 23:46 UTC

News

Realty Income Corp reported first-quarter revenue of nearly $1.55 billion, with adjusted funds from operations increasing to $1.06 billion. Shares were roughly flat after-market.

2026. aug. 3. 23:41 UTC

News

Teladoc Health remains effectively unchanged in after-market trading. Citigroup lowered its price target from $11.00 to $7.50 while maintaining a "neutral" rating.

2026. aug. 3. 23:41 UTC

News

Addus Homecare Corp reported Q2 revenue of $377.4 million and adjusted EPS of $1.73. Shares declined after the earnings announcement amid mixed market reactions.

2026. aug. 3. 23:41 UTC

News

Hims & Hers Health shares are higher in after-market trading, following positive growth insights despite facing a lawsuit from the Federal Trade Commission.

2026. aug. 3. 23:41 UTC

Correlated Moves
News

DA Davidson raised its price target for First Business Financial Services to $80, contributing to higher shares in after-market trading.

2026. aug. 3. 23:41 UTC

News

Karyopharm Therapeutics shares are lower in after-market hours following the grant of restricted stock units to a new employee, raising potential dilution concerns.

2026. aug. 3. 23:41 UTC

News

Andersons Inc. shares rise in after-market trading following strong Q2 results, with adjusted net income of $73.6 million exceeding expectations.

2026. aug. 3. 23:41 UTC

Social Media
News

BWX Technologies shares are lower in after-market hours following a revenue miss of $901.6 million and a divestiture of its medical business to Nordic Capital.

2026. aug. 3. 23:41 UTC

Social Media
News

Williams Companies announced an agreement to acquire Momentum Midstream for up to $5.5 billion, boosting its natural gas infrastructure and supporting Gulf Coast demand.

2026. aug. 3. 23:41 UTC

News

Ichor Holdings shares lower in after-market trading following a revenue miss of $294.8 million and EPS of $0.03, below expectations.

2026. aug. 3. 23:31 UTC

News

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

2026. aug. 3. 23:31 UTC

News

Ameresco shares rose in after-market trading following strong Q2 results, with revenues of $515.5 million exceeding expectations and a record $1.8 billion in new project awards.

2026. aug. 3. 23:31 UTC

News

UBS raised its price target on Colgate-Palmolive Co to $109, maintaining a Buy rating. Shares are trading higher in after-market hours.

2026. aug. 3. 23:31 UTC

Social Media
News

Grab Holdings reported strong Q2 results, with earnings per share of 6 cents and revenue of $997 million. Shares are higher in after-market hours.

2026. aug. 3. 23:31 UTC

News

Ultra Clean Holdings reported Q2 net income of $11.9 million and revenue of $644.9 million, raising its Q3 outlook to between $700 million and $750 million.

2026. aug. 3. 23:26 UTC

Social Media
News

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, exceeding estimates. The company raised its full-year guidance to between $13.1 billion and $13.2 billion.

2026. aug. 3. 23:21 UTC

News

Banner Corp announces a buyback of up to 1.7 million shares, aiming to enhance long-term shareholder value. Shares are higher in after-market trading.

2026. aug. 3. 23:21 UTC

News

Inspire Medical Systems reported Q2 adjusted EPS of $0.14, exceeding expectations. The company raised its full-year EPS guidance to between $1.05 and $1.45.

Társak összehasonlítása

Árváltozás

Heron Therapeutics Inc Előrejelzés

Célár

By TipRanks

292.16% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 2 USD  292.16%

Magas 2 USD

Alacsony 2 USD

2 Wall Street elemző 12 hónapos célárain alapulva a(z)Heron Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

2 ratings

1

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

151 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat